TREATMENT OF STROKE BY AMNIOTIC FLUID DERIVED STEM CELL CONDITIONED MEDIA AND PRODUCTS DERIVED THEREOF

    公开(公告)号:US20180085405A1

    公开(公告)日:2018-03-29

    申请号:US15717810

    申请日:2017-09-27

    IPC分类号: A61K35/50

    摘要: Disclosed are compositions of matter useful for treatment of stroke derived from amniotic fluid stem cell produced factors. In one embodiment the invention teaches the use of products derived from amniotic fluid stem cells cultured under basal conditions. In another embodiment the invention teaches the utilization of amniotic stem cell derived products from said amniotic stem cells cultured under conditions of stress. Said amniotic stem cell derived products include small molecules, proteins, peptides, conditioned media, microvesicles, including exosomes and apoptotic bodies. In one embodiment, the invention teaches administration of amniotic fluid stem cells that have been exposed to a stress condition.

    Novel cell-derived composition
    3.
    发明申请
    Novel cell-derived composition 审中-公开
    新型细胞衍生组合物

    公开(公告)号:US20170035812A1

    公开(公告)日:2017-02-09

    申请号:US15289362

    申请日:2016-10-10

    IPC分类号: A61K35/50 C12N5/073

    摘要: The invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties. In particular, the invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties termed Amnion-derived Cellular Cytokine Solution-B (ACCS-B). The invention is further directed to the use of this novel composition to promote bone growth and/or regeneration and/or repair.

    摘要翻译: 本发明涉及具有骨生长,再生和修复促进特性的新型细胞衍生组合物。 特别地,本发明涉及一种具有骨生长,再生和修复促进性质的新型细胞衍生组合物,称为羊膜衍生的细胞因子溶液-B(ACCS-B)。 本发明还涉及这种新型组合物用于促进骨生长和/或再生和/或修复的用途。

    Use of Stem Cells to Reduce Leukocyte Extravasation
    4.
    发明申请
    Use of Stem Cells to Reduce Leukocyte Extravasation 审中-公开
    使用干细胞减少白细胞外渗

    公开(公告)号:US20140134137A1

    公开(公告)日:2014-05-15

    申请号:US14070075

    申请日:2013-11-01

    申请人: Wouter Van't Hof

    发明人: Wouter Van't Hof

    IPC分类号: C12N5/078

    摘要: The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential.

    摘要翻译: 本发明一般涉及通过分泌能减少白血球外渗的因子的细胞减少炎症。 具体地,本发明涉及使用分泌下调白细胞中细胞粘附分子表达的因子的细胞的方法。 细胞粘附分子的下调表达降低白细胞对内皮细胞的粘附,从而降低外渗。 最终的结果是减少炎症。 细胞是具有多能特征的非胚胎非生殖细胞。 这些可能包括多能标记物的表达和广泛的分化潜能。

    Method for Treating Diabetes and Other Glucose Regulation Disorders Using Stem Cells

    公开(公告)号:US20170327794A1

    公开(公告)日:2017-11-16

    申请号:US15442991

    申请日:2017-02-27

    申请人: InCube Labs, LLC

    发明人: Mir Imran

    IPC分类号: C12N5/071 A61K35/38

    摘要: Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food.

    Cell-derived composition
    6.
    发明授权
    Cell-derived composition 有权
    细胞来源组成

    公开(公告)号:US09464272B2

    公开(公告)日:2016-10-11

    申请号:US14567457

    申请日:2014-12-11

    申请人: Stemnion, Inc.

    IPC分类号: C12N5/073 A61K35/50 A61K38/19

    摘要: The invention is directed to a cell-derived composition having bone growth, regeneration, and repair promoting properties. In particular, the invention is directed to a cell-derived composition having bone growth, regeneration, and repair promoting properties termed Amnion-derived Cellular Cytokine Solution-B (ACCS-B). The invention is further directed to the use of this composition to promote bone growth and/or regeneration and/or repair.

    摘要翻译: 本发明涉及具有骨生长,再生和修复促进特性的细胞衍生组合物。 特别地,本发明涉及一种具有称为淀粉衍生的细胞因子溶液-B(ACCS-B)的骨生长,再生和修复促进特性的细胞衍生组合物。 本发明进一步涉及这种组合物用于促进骨生长和/或再生和/或修复的用途。

    COMPOSITIONS FOR CELLULAR RESTORATION AND METHODS OF MAKING AND USING SAME
    7.
    发明申请
    COMPOSITIONS FOR CELLULAR RESTORATION AND METHODS OF MAKING AND USING SAME 有权
    用于细胞恢复的组合物及其制备和使用方法

    公开(公告)号:US20160145571A1

    公开(公告)日:2016-05-26

    申请号:US14889942

    申请日:2014-04-09

    IPC分类号: C12N5/074 A61K35/545

    摘要: A method comprising obtaining a donor composition from a donor subject wherein the donor composition comprises a plurality of adult stem cell types; obtaining a receiver composition from a receiver subject wherein the receiver composition comprises a plurality of adult stem cell types; and co-culturing the donor composition and receiver composition wherein co-culturing comprises contacting the receiver composition a cell-free portion of the donor composition to produce a restored composition. Pharmaceutical compositions comprising a restored composition.

    摘要翻译: 一种方法,包括从供体受试者获得供体组合物,其中所述供体组合物包含多种成体干细胞类型; 从接收者对象获得接收器组合物,其中所述接收器组合物包括多个成体干细胞类型; 以及共培养供体组合物和接受组合物,其中共培养包括使接受组合物接触供体组合物的无细胞部分以产生恢复的组合物。 包含还原组合物的药物组合物。

    Novel Cell-derived Composition
    8.
    发明申请
    Novel Cell-derived Composition 有权
    新型细胞衍生组合物

    公开(公告)号:US20150166951A1

    公开(公告)日:2015-06-18

    申请号:US14567457

    申请日:2014-12-11

    申请人: Stemnion, Inc.

    IPC分类号: C12N5/073 A61K35/50

    摘要: The invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties. In particular, the invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties termed Amnion-derived Cellular Cytokine Solution-B (ACCS-B). The invention is further directed to the use of this novel composition to promote bone growth and/or regeneration and/or repair.

    摘要翻译: 本发明涉及具有骨生长,再生和修复促进特性的新型细胞衍生组合物。 特别地,本发明涉及一种具有骨生长,再生和修复促进性质的新型细胞衍生组合物,称为羊膜衍生的细胞因子溶液-B(ACCS-B)。 本发明还涉及这种新型组合物用于促进骨生长和/或再生和/或修复的用途。